Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in overall survival (from 4.2 months to 6.1 months) for pancreatic cancer patients compared to patients just taking the other two drugs. This was particularly good news considering that MM-398 had previously failed a trial as a monotherapy.

Of course, the drug still needs to go through the FDA approval process, but if it hits the market, what are its chances of grabbing market share in this hard-to-treat cancer? In the video below, Motley Fool health care analysts David Williamson and Michael Douglass discuss the drug and its opportunities if approved.

David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.